PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy

People's Hospital of Zhengzhou University

Status: Completed

Conditions: T2DM (Type 2 Diabetes Mellitus)

Treatments: Drug: Metformin

Study type: Observational

Funder types: Other

Identifiers

NCT03155087

2016ys5

Details and patient eligibility

About

Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on PRKAA2, STK11 and diabetes, this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients, discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects.

Enrollment: 750 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosed with T2DM in keeping with the WHO criteria in 1999 [14], with fasting blood glucose (FBG) ≥ 7.0mmol ⁄ L and ⁄ or postprandial blood glucose (PBG) ≥ 11.1mmol ⁄ L; not using other antidiabetic drugs within the experimental period.

Exclusion criteria

• other significant illness such as cancer, myocardial infarction, stroke, severe liver, and kidney disease

Trial design

750 participants in 2 patient groups

T2DM patients

Description:

Metformin dosages ranged from 500 to 2000 mg per day

Treatment:

Drug: Metformin

healthy subjects

Description:

the healthy subjects was not intervened